Home / Europe / Portugal / Life Sciences & Healthcare

Life Sciences & Healthcare

In a ever-changing world, with new regulatory requirements, in which technology plays an increasingly important role in the development of global strategies, the area of health, medical devices, pharmaceuticals and new branches of sciences such as biotechnology raise several legal issues and present high complexity and specificity.

The transition to a remote and essentially digital working environment has not been particularly difficult, however, the diversity of entities involved, the existing regulation and the operation of the market itself raise several legal issues and present high complexity and specificity.

Whatever your opportunities or challenges may be, our dedicated team understands your needs and works to strategically define tailor-made solutions.

We can help you shape your strategy, manage risks and make the most of business opportunities in these areas:

  • Regulation
  • Licensing
  • Financing, mergers and acquisitions
  • Business restructuring
  • Litigation
  • Clinical Research
  • Distribution
  • Patents Protection and enforcement
  • Labelling
  • Safety and Health
  • Competition
  • Public Offers
  • Environment

We have an in-depth knowledge of how life sciences and healthcare law applies in practice across different markets and with cross-disciplinary teams, we work to provide advice close to our clients’ needs.


Feed

04/10/2024
Cannabis law and legislation in Portugal
Medical use Under the Portuguese Law, the use of cannabis for medical purposes is admissible, provided the necessary requirements and the mandatory licenses are obtained. The Portuguese legal framework...
24/09/2024
Priority entitlement: the EPO implements the new “rebuttable pre­sump­tion”...
In recent Technical Board of Appeal decision T 2360/19, the Board considered the validity of priority claims following the Enlarged Board of Appeal consolidated decision G 1/22 and G 2/22.The opposed...
09/08/2024
Antibody Appeals Uncovered
Since the first approval of Muromonab-CD3 in 1986, antibodies have become progressively more common, frequently reaching a ‘block­buster’ status. According to statistics provided by Statista in March...
25/07/2024
EU anti-dumping investigations of Chinese glyoxylic acid imports
On 25 July 2024, the EU opened an anti-dumping in­vest­ig­a­tion con­cern­ing EU imports of glyoxylic acid originating in the People’s Republic of China, which could lead to substantial anti-dumping duties...
19/07/2024
A healthy balance between novelty and sufficiency for a claimed therapeutic...
The question of novelty and sufficiency of second medical use claims in light of clinical trial prior art has been addressed by the EPO Boards of Appeal on a number of occasions. In recent decision T...
26/06/2024
Updated CMS Expert Guide to Cannabis law and legislation
CMS Expert Guide on cannabis law and legislation gives stakeholders detailed and updated information on the latest developments in cannabis regulation in key markets.  The Guide now covers 33 jurisdictions...
13/06/2024
What’s in a name? The use of a product code in a clinical trial protocol...
The use of product or sponsor codes in clinical trial related documents is common practice in the pharmaceutical space. However, such codes may not always be sufficient to disregard a publication as relevant...
21/05/2024
Consultation of the European Commission on Vifor's commitments concerning...
In response to the Preliminary Assessment stating the potential abuse of its dominant position, Vifor proposed several commitments to rectify the potential competition law infringement. The European Commission...
16/05/2024
A broader interpretation of "substance or composition" - good news for...
A recent decision from the EPO Boards of Appeal (T 1252/20) potentially paves the way for more diverse products to be patentable in Europe using the medical use claim format.The back­ground:Art­icle 53(c)...
08/05/2024
Pharmaceutical advertising regulation and medical device advertising in...
1. Which laws are applicable regarding advertising of medicines and medical devices? For all matters not foreseen in the Legal Regime of Human Medicinal Products or the Regulation on Medical Devices...
29/04/2024
On your radar | Key employment issues to be aware of internationally
We are delighted to share with you our latest and largest edition of On Your Radar, with contributions from 35 coun­tries.   As ever, you will find employment law updates covering a diverse range of...
11/04/2024
Navigating clinical trial disclosures: No reasonable expectation of success...
Recent EPO Board of Appeal decision T 1437/21 adds to a growing number of decisions concerning the patentability of second or further medical use inventions where the prior art relates to a clinical trial...